Ideaya Biosciences (IDYA) announced the clearance of an Investigational New Drug, or IND, application with the FDA for initiation of a GSK-sponsored (GSK) Phase 1/2 clinical trial to evaluate GSK101, a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of poly-polymerase, or PARP, for the treatment of patients having tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences doses first patient in darovasertib trial
- Ideaya Biosciences price target raised to $40 from $35 at Wedbush
- Ideaya Biosciences price target raised to $35 from $30 at Oppenheimer
- IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- Ideaya Biosciences reports Q2 EPS (50c), consensus (56c)